BRPI0821683A2 - Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético - Google Patents
Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatéticoInfo
- Publication number
- BRPI0821683A2 BRPI0821683A2 BRPI0821683-5A BRPI0821683A BRPI0821683A2 BR PI0821683 A2 BRPI0821683 A2 BR PI0821683A2 BR PI0821683 A BRPI0821683 A BR PI0821683A BR PI0821683 A2 BRPI0821683 A2 BR PI0821683A2
- Authority
- BR
- Brazil
- Prior art keywords
- agonist
- sympathetic
- medicament
- parasympathetic
- antagonist
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 2
- 230000002889 sympathetic effect Effects 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001734 parasympathetic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724558.2A GB0724558D0 (en) | 2007-12-15 | 2007-12-15 | Optical correction |
| PCT/GB2008/004129 WO2009077736A2 (en) | 2007-12-15 | 2008-12-15 | Optical correction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0821683A2 true BRPI0821683A2 (pt) | 2015-06-16 |
| BRPI0821683B1 BRPI0821683B1 (pt) | 2019-11-05 |
| BRPI0821683B8 BRPI0821683B8 (pt) | 2021-05-25 |
Family
ID=39048209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0821683A BRPI0821683B8 (pt) | 2007-12-15 | 2008-12-15 | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20090156606A1 (pt) |
| EP (3) | EP3031457B1 (pt) |
| CN (1) | CN101969940A (pt) |
| AU (1) | AU2008337350A1 (pt) |
| BR (1) | BRPI0821683B8 (pt) |
| CA (1) | CA2747095C (pt) |
| ES (2) | ES2725002T3 (pt) |
| GB (1) | GB0724558D0 (pt) |
| WO (1) | WO2009077736A2 (pt) |
| ZA (1) | ZA201005026B (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| UA113525C2 (xx) * | 2011-09-20 | 2017-02-10 | Спосіб лікування пресбіопії | |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| PT3500255T (pt) | 2016-08-19 | 2023-01-10 | Orasis Pharmaceuticals Ltd | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas |
| WO2018054489A1 (en) * | 2016-09-23 | 2018-03-29 | Hallboeoek Finn | Pharmacological treatment of myopia |
| CA3070556A1 (en) * | 2017-07-20 | 2019-01-24 | Alan Laboratories, Inc. | Compositions and methods for treatment of myopia |
| SG11202004019SA (en) | 2017-11-17 | 2020-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of eye disorders |
| MX392359B (es) * | 2017-11-17 | 2025-03-24 | Cellix Bio Private Ltd | Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas |
| PL3681500T3 (pl) | 2018-04-24 | 2022-08-01 | Allergan, Inc. | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| EP3866790A4 (en) | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| JP7670945B2 (ja) | 2018-10-26 | 2025-05-01 | オーパス・ジェネティクス・インコーポレイテッド | 老眼、散瞳、および他の眼障害の治療のための方法および組成物 |
| US20200297720A1 (en) * | 2019-03-22 | 2020-09-24 | Baradaina LLC | Methods of Treating Eye Disorders |
| CA3138510A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
| CN114502155A (zh) * | 2019-06-10 | 2022-05-13 | 视觉治疗股份有限公司 | 增强抗老视作用的卡巴胆碱-溴莫尼定制剂 |
| WO2020252057A1 (en) | 2019-06-10 | 2020-12-17 | Visus Therapeutics, Inc. | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality |
| MX394625B (es) * | 2020-11-12 | 2025-03-24 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| CN117529316A (zh) * | 2021-04-23 | 2024-02-06 | 奥库菲尔制药股份有限公司 | 用于治疗瞳孔散大、青光眼和其他眼部病症的方法和组合物 |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| TW202333662A (zh) | 2021-11-10 | 2023-09-01 | 美商偉視醫療股份有限公司 | 增強抗老花眼效果之卡巴可(carbachol)調配物 |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US12156868B2 (en) * | 2022-02-09 | 2024-12-03 | Somerset Therapeutics, Llc | Formulations of pilocarpine and brimonidine compounds and related methods |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3883225A (en) * | 1972-11-06 | 1975-05-13 | Donald S Rehm | Methods and apparatus for treating acquired myopia and similar or related eye conditions |
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
| JPH07508751A (ja) * | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
| CA2319649A1 (en) * | 1998-01-28 | 1999-08-05 | Mitsunori Waki | Preventives or remedies for vision disorders |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20040116524A1 (en) * | 2002-02-04 | 2004-06-17 | Cohen Ben Z. | Method of administering opthalmic fluids |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| CA2546042A1 (en) * | 2003-11-20 | 2005-06-09 | Othera Pharmaceuticals, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| US7479277B2 (en) * | 2005-02-24 | 2009-01-20 | Wisconsin Alumni Research Foundation | Method for reducing intraocular pressure using integrin-linked kinase inhibitor |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| ES2329161T3 (es) | 2006-12-18 | 2009-11-23 | Jorge Luis Benozzi | Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia. |
| EP2097044A4 (en) | 2006-12-26 | 2012-10-10 | Quadra Logic Tech Inc | DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
-
2007
- 2007-12-15 GB GBGB0724558.2A patent/GB0724558D0/en not_active Ceased
-
2008
- 2008-12-15 CN CN2008801268956A patent/CN101969940A/zh active Pending
- 2008-12-15 ES ES16000001T patent/ES2725002T3/es active Active
- 2008-12-15 EP EP16000001.4A patent/EP3031457B1/en not_active Not-in-force
- 2008-12-15 CA CA2747095A patent/CA2747095C/en not_active Expired - Fee Related
- 2008-12-15 EP EP08861490.4A patent/EP2242487B1/en not_active Not-in-force
- 2008-12-15 WO PCT/GB2008/004129 patent/WO2009077736A2/en not_active Ceased
- 2008-12-15 EP EP19000065.3A patent/EP3505169B1/en not_active Not-in-force
- 2008-12-15 US US12/334,916 patent/US20090156606A1/en not_active Abandoned
- 2008-12-15 AU AU2008337350A patent/AU2008337350A1/en not_active Abandoned
- 2008-12-15 BR BRPI0821683A patent/BRPI0821683B8/pt not_active IP Right Cessation
- 2008-12-15 ES ES08861490.4T patent/ES2572750T3/es active Active
-
2010
- 2010-07-15 ZA ZA2010/05026A patent/ZA201005026B/en unknown
-
2012
- 2012-12-03 US US13/692,257 patent/US8829037B2/en active Active
-
2014
- 2014-09-08 US US14/479,852 patent/US9623007B2/en not_active Expired - Fee Related
-
2017
- 2017-04-18 US US15/489,950 patent/US11278545B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201005026B (en) | 2011-03-30 |
| US9623007B2 (en) | 2017-04-18 |
| BRPI0821683B1 (pt) | 2019-11-05 |
| CA2747095C (en) | 2020-02-18 |
| AU2008337350A1 (en) | 2009-06-25 |
| US20170216281A1 (en) | 2017-08-03 |
| WO2009077736A3 (en) | 2009-12-30 |
| WO2009077736A4 (en) | 2010-02-25 |
| CN101969940A (zh) | 2011-02-09 |
| CA2747095A1 (en) | 2009-06-25 |
| ES2572750T3 (es) | 2016-06-02 |
| US20140378519A1 (en) | 2014-12-25 |
| GB0724558D0 (en) | 2008-01-30 |
| EP3031457B1 (en) | 2019-02-06 |
| EP2242487A2 (en) | 2010-10-27 |
| US8829037B2 (en) | 2014-09-09 |
| EP2242487B1 (en) | 2016-02-24 |
| WO2009077736A2 (en) | 2009-06-25 |
| ES2725002T3 (es) | 2019-09-18 |
| EP3505169A1 (en) | 2019-07-03 |
| US20130096131A1 (en) | 2013-04-18 |
| US20090156606A1 (en) | 2009-06-18 |
| EP3031457A1 (en) | 2016-06-15 |
| BRPI0821683B8 (pt) | 2021-05-25 |
| US11278545B2 (en) | 2022-03-22 |
| EP3505169B1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0821683A2 (pt) | Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético | |
| LTC2379069I2 (lt) | S1p receptoriaus agonisto dozavimas | |
| NO2022018I1 (no) | Avacopan samt farmaceutisk acceptable salte deraf | |
| HRP20151108T1 (xx) | Antagonisti nogo-receptora | |
| DK2311622T3 (da) | Sprøjteformet genstand med en udmærket barriereegenskab | |
| EP2051734A4 (en) | MEDIUM FOR ADMINISTRATION IN THE BLOOD BRAIN BARRIERS | |
| BRPI0814547A2 (pt) | Dispositivo de prevenção de picada de agulha | |
| DK2384754T3 (da) | Farmaceutiske doseringsformer | |
| NO20090079L (no) | Arylsulfonamider med analgesisk virkning | |
| DK2381986T3 (da) | Lægemiddeladministrationsanordning | |
| ATE484305T1 (de) | Nadelsicherheitsvorrichtung | |
| DK2117521T3 (da) | Transdermale indgivelsessystemer omfattende bupivacain | |
| BRPI1014877A8 (pt) | compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico. | |
| BRPI0810926A2 (pt) | Antagonista de crig | |
| BRPI0818493A2 (pt) | Empacotador com nervuras | |
| BRPI0817835A2 (pt) | Antagonistas cgrp | |
| DK2252581T3 (da) | Kappa-selektiv opioidreceptorantagonist | |
| BRPI0716893A2 (pt) | Forma de dosagem sólida de olmesartan medoxomila e anlodipina | |
| EP1999805A4 (en) | SECONDARY BATTERY IMPROVED SAFETY | |
| BRPI0816425A2 (pt) | Barreira portátil | |
| DE502007003750D1 (de) | Klemmvorrichtung | |
| EP2197448A4 (en) | dosing schedule | |
| HRP20160950T1 (hr) | Polimorfi antagonista mglur5 receptora | |
| DK2131818T3 (da) | Ny doseringsform | |
| BRPI0908008A2 (pt) | Farmacóforo dual - pde4-antagonistas muscarínicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2805 DE 08-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |